ROSETTA GENOMICS
leading the microRNA revolution

miRview™ | mets
Take a closer look

Cat#0802

PATIENT REPORT

Patient Information

Name:
SSN/ID #:
Date of Birth:
Gender:

Ordering Physician Information

Ordering Physician Name:
Address:
City: State: Zip:
Country:
Phone #:
Fax #:
Report Delivery Preference: ☐ Overnight mail ☐ Fax

Test Results

Tissue of Origin:
Histological Type:
2nd most Likely Tissue of origin:
2nd most Likely Histological Type:

Test Description

miRview ™ mets assay quantifies the expression of 48 microRNAs to determine tissue of origin in metastatic cancer. Initially, an adequate ratio of tumor to surrounding tissue is ascertained, depending on sample characteristics microdissection is performed, and after RNA extraction, qRT-PCR is performed. The test was developed with and can discriminate among 17 tissues of origin and 25 histologic types (please see notes) by using a combination of a proprietary binary decision tree and K Nearest Neighbor (KNN) classifier. When the binary tree classification and the KNN classification agree, only one origin is reported, otherwise, both origins are reported. The result determined by the KNN classification is reported as the most likely origin, and the binary tree classification is reported as the second most likely.

Interpretation of Results

Based on validation studies, the overall sensitivity and specificity of this assay for the detection of the tissue of origin, when the sample contains 50% tumor or greater, were 84% and 97%, respectively. In validation studies, the majority of cases returned a single predicted origin. For these cases, the sensitivity and specificity were 90% and 99%, respectively.

Account Information

Account name:
Address:
City: State: Zip:
Country:
Phone #:
Fax #:
Report Delivery Preference: ☐ Overnight mail ☐ Fax

Specimen Information

Specimen Type: Formalin-fixed paraffin embedded tissue
Biopsy Site:
Specimen Collection Date:
Subm. Lab Access. #:
Date Specimen Received:
Barcode #:
Sample ID #:
Date Result Reported:

Note

a. The performance characteristics of this test were determined by Rosetta Genomics in accordance with the requirements of CLIA (Clinical Laboratory Improvement Amendments of 1988). It has not been cleared or approved by the U.S. Food and Drug Administration. This test is intended to be used for clinical purposes and should not be considered to be for investigational or research use only. Decisions regarding care and treatment should be based on the independent medical judgment of the treating physician taking into consideration all available information concerning the patient's condition, including other tests.

b. Performance: The miRview mets test has been developed using the following set of primary origins: Biliary tract cancer; Brain: astrocytoma, oligodendroglioma; Breast adenocarcinoma; Colonic adenocarcinoma; Squamous cell carcinoma of the esophagus; Squamous cell carcinoma of the head and neck; Hepatocellular carcinoma; Lung: squamous cell carcinoma, adenocarcinoma, large cell carcinoma, small cell carcinoma, carcinoid; Melanoma; Ovary: endometrioid carcinoma, serous carcinoma; Pancreatic adenocarcinoma; Prostatic adenocarcinoma; Renal cell carcinoma; Gastric adenocarcinoma; Adenocarcinoma of the esophagus; Testis: seminoma, non-seminomatous testicular cancer; Thymoma; Thyroid: follicular carcinoma, papillary carcinoma, medullary carcinoma. Origins not included in the above list will not be identified by the assay.

Laboratory Director
Tina Edmonston, MD

ROSETTA GENOMICS
leading the microRNA revolution

miRview™ | mets
Take a closer look

Cat#0802

PATIENT REPORT